FDA tags psilocybin drug as clinical depression Breakthrough TherapyThe FDA has tagged psilocybin, the illegal psychoactive compound found in ‘magic mushrooms’, as a potential breakthrough treatment Share XFDA tags psilocybin drug as clinical depression Breakthrough Therapyhttps://pharmaphorum.com/news/fda-tags-psilocybin-drug-as-clinical-depression-breakthrough-therapy/
J&J seeks wider use of its Spravato antidepressant in USJohnson & Johnson has filed for US approval for a new claim on the label for its nasal Share XJ&J seeks wider use of its Spravato antidepressant in UShttps://pharmaphorum.com/news/jj-seeks-wider-use-of-its-spravato-antidepressant-in-us/
J&J’s Spravato for depression ‘should be much cheaper’Johnson & Johnson has priced its new Spravato nasal spray for treatment-resistant depression (TRD) too high to offer Share XJ&J’s Spravato for depression ‘should be much cheaper’https://pharmaphorum.com/news/jjs-spravato-for-depression-should-be-much-cheaper/
Abilify MyCite and innovating in digital healthpharmaphorum’s Paul Tunnah spoke with Otsuka Pharmaceutical’s North America Pharmaceutical Business president and CEO Kabir Nath about the Share XAbilify MyCite and innovating in digital healthhttps://pharmaphorum.com/views-analysis-digital/abilify-mycite-and-innovating-in-digital-health/
FDA approves Janssen’s ketamine-based nasal antidepressantThe FDA has approved Janssen’s antidepressant nasal spray Spravato, making it the first new type of depression treatment Share XFDA approves Janssen’s ketamine-based nasal antidepressanthttps://pharmaphorum.com/news/fda-approves-janssens-ketamine-based-nasal-antidepressant/
FDA panel backs J&J’s potential depression blockbusterA panel of advisers to the FDA has voted in favour of approving Johnson & Johnson’s experimental nasal Share XFDA panel backs J&J’s potential depression blockbusterhttps://pharmaphorum.com/news/fda-panel-backs-jjs-potential-depression-blockbuster/
NICE backs digital CBT for youngsters with depressionNICE has recommended digital cognitive behavioural therapy (CBT) should be used as a first-line treatment for children and Share XNICE backs digital CBT for youngsters with depressionhttps://pharmaphorum.com/news/nice-backs-digital-cbt-for-youngsters-with-depression/
Otsuka funds prescription therapy app for depressionOtsuka is once again betting on digital as a new avenue for depression treatment by collaborating with Click Share XOtsuka funds prescription therapy app for depressionhttps://pharmaphorum.com/news/otsuka-funds-app-depression/
J&J preps for FDA panel grilling over depression drugJohnson & Johnson is “confident” about regulatory reviews of its depression drug esketamine ahead of a likely grilling Share XJ&J preps for FDA panel grilling over depression drughttps://pharmaphorum.com/news/janssen-preps-for-fda-panel-grilling-esketamine/
